Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves Boxed Warning On Cancer Risk For Elidel And Protopic

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency finalized the addition of the boxed warnings and revised indications for the eczema therapies' labels one year after a similar recommendation by an FDA advisory committee.

You may also be interested in...



Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity

New treatments for atopic dermatitis – including the first biologic medicine for the disease – could launch next year, fueling substantial growth in a therapy area where there have been few advances. Payers, however, will be keeping an eye on the cost.

Novartis, Astellas Intend To Disprove Eczema Treatments’ Cancer Risk

Novartis and Astellas aim to use ongoing studies to convince FDA to remove a requirement for a "black box" warning of potential cancer risk in labeling for their topical calcineurin inhibitors

Novartis, Astellas Intend To Disprove Eczema Treatments’ Cancer Risk

Novartis and Astellas aim to use ongoing studies to convince FDA to remove a requirement for a "black box" warning of potential cancer risk in labeling for their topical calcineurin inhibitors

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel